Research

Zacks Small Cap Research – SUUN: The future is bright! Initiating coverage of an emerging solar developer and power producer – Go Health Pro

by

By Brian Lantier, CFA NASDAQ:SUUN READ THE FULL SUUN RESEARCH REPORT SolarBank (NASDAQ:SUUN) is a vertically integrated solar and battery energy storage system (BESS) project developer, engineering, procurement, construction service provider (EPC), and independent power producer (IPP) principally focused on community solar and corporate projects in New York and Ontario. As the company moves into … Read more

Zacks Small Cap Research – OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR – Go Health Pro

by

NASDAQ:COCP John M. Viglotti: Hello and welcome to Virtual Investor Conferences. On behalf of the Life Sciences Investor Forum and our co-host, Zacks Small Cap Research, we’re very pleased you joined us for our quarterly conference. Our next live presentation is from Cocrystal Pharma. Cocrystal is a clinical-stage biotech company developing novel antiviral therapeutics. Please … Read more

Zacks Small Cap Research – LGMK: Potential Revenue Catalysts: GSA Approval, Medicaid Waivers, Device Upgrades – Go Health Pro

by
Zacks Small Cap Research – LGMK: Potential Revenue Catalysts: GSA Approval, Medicaid Waivers, Device Upgrades – Go Health Pro

By M. Marin NASDAQ:LGMK READ THE FULL LGMK RESEARCH REPORT Recent introduction of next-gen Guardian Alert 911 Plus in 1Q25… LogicMark, Inc. (NASDAQ:LGMK) launched the next generation of the Guardian Alert 911 Plus in February 2025. The next-generation Guardian Alert 911 Plus expands the company’s product suite and offers an upgrade from the earlier version … Read more

Zacks Small Cap Research – DWTX: Interim Data for Phase 2b Trial in 4Q25… – Go Health Pro

by
Zacks Small Cap Research – DWTX: Interim Data for Phase 2b Trial in 4Q25… – Go Health Pro

By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced that the first patient was dosed in the Phase 2b HALT-CINP (Halneuron Treatment of Chemotherapy-Induced Neuropathic Pain) trial. This is a four-week study that … Read more

Zacks Small Cap Research – CTSO: CytoSorbents Reports 4th quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Update on the DrugSorb-ATR Regulatory Process Management reiterated that their De Novo DrugSorb-ATR submission continued to be in interactive review with FDA, that their Medical Device License application to Health Canada was in advanced review, and that they continue to expect regulatory decisions in … Read more